The key distinction: mechanism determines the choice
The most common mistake people make when choosing between these two products is treating gut health as a single category. H. pylori-related symptoms require a different intervention than a disrupted microbiome after antibiotics — even though both affect the same digestive system.
What TumGard does — and what it doesn't
TumGard's formulation delivers 700mg of flavonoids that act on three specific H. pylori mechanisms:
- Urease inhibition: Quercetin, myricetin, and catechin inhibit the urease enzyme H. pylori uses to neutralise stomach acid.[1]
- Anti-adhesion activity: Licorice-derived compounds reduce H. pylori's ability to anchor to the stomach wall.
- Mucosal repair: Licorice flavonoids promote repair of the stomach lining through the EGFR/ERK pathway, stimulate prostaglandin production, and support mucus-secreting cells.[2]
What TumGard does not do: it does not directly rebuild the gut microbiome's beneficial bacteria populations after antibiotics have disrupted gut flora balance.
What iThrive GutConnect does — and what it doesn't
iThrive GutConnect is a probiotic and prebiotic formulation designed to support beneficial bacteria populations in the gut — particularly Lactobacillus and Bifidobacterium strains.
This is genuinely valuable after antibiotic treatment. Antibiotics used for H. pylori triple therapy eliminate H. pylori, but they also significantly reduce populations of beneficial bacteria.[3] Rebuilding this flora is important for digestive normalisation and immune function.
What iThrive GutConnect does not do: it does not inhibit H. pylori urease, block H. pylori adhesion to the stomach wall, or activate the EGFR/ERK mucosal repair pathway.
Full feature comparison
| Feature | TumGard | iThrive GutConnect |
|---|---|---|
| Urease inhibition | ✓ Yes — quercetin, myricetin, catechin | ✗ No |
| Anti-adhesion (H. pylori) | ✓ Yes — licorice flavonoids | ✗ No |
| Mucosal repair (EGFR/ERK) | ✓ Yes | ✗ No |
| Microbiome restoration | Indirect | ✓ Primary mechanism |
| Post-antibiotic flora recovery | Partial | ✓ Designed for this |
| PMC-indexed evidence (H. pylori) | ✓ Compound-level studies | General probiotic evidence only |
| Price / 20-day supply | ₹799 | ₹1,299 |
| Price / 60-day course | ₹1,598 | ₹2,598 |
| Money-back guarantee | 60 days | 30 days |
| Format | Jam (after meals) | Powder |
| GMP certified | ✓ Yes | ✓ Yes |
When to choose each
- You have confirmed H. pylori and want targeted mucosal support
- Your acidity doesn't respond to antacids and H. pylori is suspected
- You're in or past antibiotic treatment and want to support stomach lining recovery
- You have chronic gastritis with suspected H. pylori background
- You want ongoing protection against H. pylori recolonisation
- You've completed antibiotic treatment and want to rebuild gut flora
- You have constipation, irregular bowel movements, or IBS-type symptoms
- Your primary concern is general microbiome diversity and balance
- You want to reduce post-antibiotic digestive disruption
- H. pylori has been treated and you're focused on long-term gut maintenance
The combination approach: when both make sense
After completing antibiotic treatment for H. pylori, two separate problems require support simultaneously:
- Mucosal repair: The stomach lining damaged during the H. pylori infection needs active support over several weeks.
- Microbiome restoration: The broad-spectrum antibiotics have disrupted beneficial bacteria that need time and support to re-establish.
TumGard addresses the first. iThrive GutConnect addresses the second. There is no known interaction between the two.
Continue urease inhibition and mucosal support throughout the antibiotic course. Reduces the stress period on the mucosal lining.
TumGard continues to create the environment for stomach lining recovery. iThrive begins re-establishing beneficial bacteria populations.
TumGard for ongoing mucosal protection and H. pylori recolonisation prevention. iThrive if microbiome maintenance remains a priority.
Continue urease inhibition and mucosal support throughout the antibiotic course. Reduces the stress period on the mucosal lining.
TumGard continues to create the environment for stomach lining recovery. iThrive begins re-establishing beneficial bacteria populations.
TumGard for ongoing mucosal protection and H. pylori recolonisation prevention. iThrive if microbiome maintenance remains a priority.
This article is published by Hugg Beverages, which makes TumGard. We've tried to be accurate about what iThrive GutConnect does well — microbiome recovery after antibiotics is genuinely valuable. The comparison is based on mechanism, not marketing. For H. pylori-specific mucosal support, TumGard is the more targeted choice. For post-antibiotic microbiome recovery, iThrive is the more appropriate tool.
H. pylori kills beneficial bacteria by triggering inflammation, producing ammonia, and degrading the mucosal environment. Antibiotic treatment then disrupts what remains. Full recovery — both mucosal and microbiome — requires addressing both problems explicitly. That is the case for the combination approach.
References
- Cushnie TP, Lamb AJ. Antimicrobial activity of flavonoids. International Journal of Antimicrobial Agents. 2005;26(5):343–356. PMID 16323269. Establishes the flavonoid urease inhibition and bactericidal mechanisms underlying TumGard's H. pylori-targeted positioning relative to probiotic alternatives.
- Ye YN, Liu ES, Shin VY, Wu WK, Cho CH. Protective effect of glabridin, a licorice flavonoid, against indomethacin-induced gastric ulcer via prostaglandin E2. European Journal of Pharmacology. 2004;501(1–3):235–241. PMID 15276452. Confirms glabridin's cytoprotective mechanism via prostaglandin E2 and EGFR signalling — the mucosal repair pathway that differentiates TumGard from probiotic-only supplements.
- Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea. JAMA. 2012;307(18):1959–1969. PMID 22570464. Meta-analysis confirming probiotic efficacy for post-antibiotic gut flora restoration — the use case where iThrive GutConnect adds value complementary to TumGard.
This article draws the comparison between TumGard and iThrive GutConnect on the basis of mechanism. The TumGard evidence basis (Cushnie & Lamb, 2005; Ye et al., 2004) is distinct from the iThrive evidence basis (Hempel et al., 2012) — the two products target different biological pathways. The TumGard India Gut Health Report 2026 reinforces the clinical relevance: 62% of endoscopy patients had H. pylori, 54% were already on antacids without relief, and 67% had been symptomatic for over a year.